Amgen reported diluted earnings per share of $0.98 for the first quarter of 2009, a decrease of 3%, compared to $1.01 per share for the first quarter of 2008.
The company reported net revenues of $3.31 billion for the first quarter of 2009, a decrease of 8%, compared to $3.61 billion for the same period of 2008.
Kevin Sharer, chairman and CEO of Amgen, said: “Our first quarter sales were affected by the continued deterioration of the global economy which has led to changes in patient and physician behavior. Our future prospects remain strong.
“We have made progress on our plans to commercialize denosumab for PMO. Also, we are looking forward to reviewing important data on pipeline products including denosumab in certain oncology indications and Vectibix in colorectal cancer.”